Acura Pharmaceuticals to Present at the Cowen Health Care Conference on March 5, 2013

Fri Feb 22, 2013 10:00am EST

* Reuters is not responsible for the content in this press release.

  PALATINE, IL, Feb 22 (Marketwire) -- 
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical
company developing products intended to address medication abuse and
misuse, announced today that the Company will present at the Cowen and
Company Health Care Conference at the Boston Marriott Copley Place on
Tuesday, March 5, 2013. Bob Jones, Acura Pharmaceutical's Chief Executive
Officer, will provide a company update at 8:40AM Eastern Time. In advance
of this presentation the Company plans to report financial results for
the fourth quarter and fiscal year ended December 2012 following the
close of markets on Monday, March 4, 2013.

     A live webcast of the presentation will be available through the
"Investors" page of Acura's website: www.acurapharm.com. An archived
version of the presentation will be available for 30 days after the event.

    About Acura Pharmaceuticals
 Acura Pharmaceuticals is a specialty
pharmaceutical company engaged in the research, development and
commercialization of product candidates intended to address medication
abuse and misuse, utilizing its proprietary AVERSION(R) and IMPEDE(TM)
technologies. AVERSION contains polymers that cause the drug to gel when
dissolved; it also contains compounds that irritate the nasal passages.
IMPEDE is designed to disrupt the processing of pseudoephedrine from
tablets into methamphetamine.

    In June 2011, the U.S. Food and Drug Administration approved OXECTA(R)
(oxycodone HC1 tablets) which incorporates the AVERSION(R) technology.
The Company has a development pipeline of additional AVERSION(R)
technology products containing other opioids. 

    In December 2012, the Company commenced commercialization of Nexafed(R)
[pseudoephedrine hydrochloride (HCl)], a 30 mg immediate-release
abuse-deterrent decongestant. The next generation pseudoephedrine tablet
combines effective nasal congestion relief with IMPEDE(TM) technology, a
unique polymer matrix that disrupts the conversion of pseudoephedrine
into the dangerous drug, methamphetamine. 

    The trademark OXECTA(R) is owned by Pfizer Inc.

    

Contact: 
for Acura Investor Relations
investors@acurapharm.com
847-705-7709

for Acura Media Relations
pr@acurapharm.com
847-705-7709 

Copyright 2013, Marketwire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.